Caris Life Sciences (CAI) Debt Ratio (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Debt Ratio of 0.33 for Q1 2026, down 2.58% quarter-over-quarter from 0.34 in Q4 2025.

Caris Life Sciences (CAI) Debt Ratio (2024 - 2026) Analysis & Trends

Caris Life Sciences' Debt Ratio history runs 3 years deep, the most recent figure standing at 0.33 for Q1 2026.

In Q1 2026, Debt Ratio changed N/A year-over-year to 0.33; the TTM figure through Mar 2026 stood at 0.33 (changed N/A YoY), while the FY2025 annual figure was 0.34, down 73.29% from the prior year.
Debt Ratio for Q1 2026 stood at 0.33, down from 0.34 in the prior quarter.
The five-year high for Debt Ratio was 1.26 in Q4 2024, with the low at 0.33 in Q1 2026.
The 3-year median for Debt Ratio is 0.38 (2025), against an average of 0.54.
Peak annual rise in Debt Ratio reached 73.29% in 2025, while the deepest fall reached 73.29% in 2025.
Caris Life Sciences' Debt Ratio stood at 1.26 in 2024, then slumped by 73.29% to 0.34 in 2025, then slipped by 2.58% to 0.33 in 2026.
Business Quant data shows CAI's Debt Ratio at 0.33 in Q1 2026, 0.34 in Q4 2025, and 0.38 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	0.32

Download Data